| Name | Title | Contact Details |
|---|
Custom Goods Logistics is a full-service logistics company based in Carson, California, with over 60 years of experience in the industry. As a nationally-recognized third-party logistics (3PL) provider, the company employs around 600 people and generates annual revenue of $195.9 million. Custom Goods operates a fleet of more than 175 trucks and manages over 7 million square feet of warehouse space across the United States. The company offers a range of logistics solutions, including warehousing, transportation, specialty freight forwarding, and centralized exam stations. Custom Goods specializes in omni-channel fulfillment, integrating e-commerce, retail, and wholesale operations with advanced inventory management. They serve various sectors, including food and beverage, retail, automotive, industrials, e-commerce, and manufacturing, providing tailored solutions to meet specific client needs. The company emphasizes data-driven decision-making, personalized customer service, and timely solutions, positioning itself as a partner dedicated to supporting business success.
A company dedicated to excellence in the insurance and financial services industries. Through data-driven management and lasting relationships, IH has built a solid foundation capable of taking companies to the next level of performance, profitability, and stability. Our business approach is straightforward. We believe that the power and success behind any business or industry lie within knowledge – knowledge of your products, the direction of your company, and the ongoing execution of a stellar strategic plan. These core assets, coupled with unmatched talent from a thriving corporate culture, are what we believe to be the key ingredients for achieving profitable, steady growth.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
One platform. Endless solutions.